Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells

This study is ongoing, but not recruiting participants.
Oxnard Foundation
Information provided by (Responsible Party):
New Mexico Cancer Care Alliance
ClinicalTrials.gov Identifier:
First received: January 8, 2013
Last updated: March 3, 2015
Last verified: March 2015

This study will investigate the possibility of using the drug thioridazine (also called Mellaril) to increase the number of certain types of cells moving from the bone marrow to the circulation in a group of healthy humans. The types of cells we hope to collect are called CD34+ progenitor, or stem cells. These cells can be used in the laboratory to better understand a number of diseases and suggest new strategies for therapy. Perhaps the most important potential application of human stem cells is the generation of cells and tissues that could be used for cell-based therapies, as a renewable source of replacement cells and tissues to treat diseases including Alzheimer's diseases, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and rheumatoid arthritis.

Condition Intervention Phase
Stem Cell Mobilization
Drug: Mellaril
Phase 0

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Single Institution Feasibility Study to Assess Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells

Resource links provided by NLM:

Further study details as provided by New Mexico Cancer Care Alliance:

Primary Outcome Measures:
  • CD34+ Progenitor Cell Mobilization [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
    To determine the dose-related CD34+ progenitor cell mobilization by thioridazine when administered as a single agent in normal (healthy) study subjects

Secondary Outcome Measures:
  • Measure side effects [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
    To describe the adverse events associated with thioridazine when administered as a single, 50 mg dose in healthy study subjects according to CTCAE version 4.

Enrollment: 6
Study Start Date: June 2013
Estimated Study Completion Date: December 2015
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Mellaril (thioridazine)
Oral Mellaril
Drug: Mellaril
Subjects will undergo a physical exam including an electrocardiogram (EKG) and have blood drawn before treatment. A single 50 gm dose of thioridazine (Mellaril) will be given to eligible subjects. Any subject who receives treatment on this protocol will be evaluable for toxicity. A second blood draw will occur at 24 hours post-treatment. All subjects will be followed for possible adverse events (toxicity) for 30 days after treatment.
Other Name: Thioridazine

Detailed Description:

This is a single-arm, feasibility study to test whether a single dose of Mellaril (thioridazine HCL) is able to effectively mobilize CD34+ cells in a set of health human subjects. This study does not involve the use of placebos, and subjects will serve as their own controls for CD34+ cell mobilization. We hypothesize that a single dose of Mellaril (thioridazine HCL) will mobilize CD34+ progenitor cells into human peripheral blood by a factor of at least 10 fold, from 4 to 40 cells/microliter.


Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy, non-smoking subjects (male or female)
  • Age: 18 to 55 years
  • All subjects must agree to refrain from consuming alcohol during for 48 hours after taking thioridazine.
  • Performance status Karnofsky score of 100%.
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • A female of child-bearing potential is any woman (regardless of sexual orientation, having not undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
  • Has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  • Ability to understand the purpose and procedures of this study, and the willingness to sign a written informed consent document.
  • Only subjects whose laboratory testing, including platelet counts and transaminase levels are within normal limits are eligible.
  • Subjects must pass pre-treatment screening by EKG to rule out long QT syndrome or subclinical cardiac arrhythmia.

Exclusion Criteria:

  • Subjects who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Agent(s) or other agents used in study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, a febrile illness within 35 days of study entry, or psychiatric illness or dementia, or social situations that would limit compliance with study requirements.
  • Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
  • Concomitant use of phenytoin excludes potential subjects from participation.
  • Subjects with known long QT syndrome or known history of cardiac arrhythmias are excluded from participation.
  • Subjects taking drugs known to inhibit P450 CYP2D6 are excluded from participation.
  • Subjects who received an investigational agent within 28 days of dosing with thioridazine on this protocol are excluded from participation.
  • Subjects who received thioridazine within 7 days of dosing on this protocol are excluded from participation.
  • Subjects who have had pelvic radiation are excluded from participation.
  • Subjects who have received myeloablative regimens at any time are excluded from participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01765803

United States, New Mexico
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
New Mexico Cancer Care Alliance
Oxnard Foundation
Principal Investigator: Stuart S Winter, MD University of New Mexico Health Sciences Center/Pediatric Oncology
  More Information

Additional Information:
No publications provided

Responsible Party: New Mexico Cancer Care Alliance
ClinicalTrials.gov Identifier: NCT01765803     History of Changes
Other Study ID Numbers: INST 1208
Study First Received: January 8, 2013
Last Updated: March 3, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by New Mexico Cancer Care Alliance:
Stem cells
Progenitor cells
Peripheral blood
peripheral blood

Additional relevant MeSH terms:
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on July 01, 2015